The inhalation company Inhalation Sciences has received an IRS order from a new European pharmaceutical customer, with a value of approximately SEK 1.3 million. This is stated in a press release.The assignment includes preclinical studies in which the company's PreciseInhale technology is used to analyze how inhaled substances behave in living organisms.“The order reflects growing confidence in our ability to support complex inhalation research,” says CEO Manoush Masarrat.